ProQR Therapeutics NVNASDAQ:PRQR
- LAST PRICE1.9900
- TODAY'S CHANGE (%)0.1300 (6.9892%)
- Bid / Lots1.9300/ 3
- Ask / Lots1.9900/ 1
- Open / Previous Close1.9000 / 1.8600
- Day Range
- 52 Week Range
- Volume134,020
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRQR |
|---|---|---|
| 09:32 ET | 10480 | 2 |
| 09:36 ET | 1300 | 1.98 |
| 09:39 ET | 1000 | 1.9199 |
| 09:43 ET | 100 | 1.97 |
| 09:45 ET | 300 | 1.87 |
| 09:48 ET | 600 | 1.95 |
| 09:50 ET | 5100 | 1.94 |
| 09:52 ET | 2426 | 1.97 |
| 09:54 ET | 400 | 1.9674 |
| 09:56 ET | 400 | 1.99 |
| 09:57 ET | 1100 | 1.965 |
| 09:59 ET | 2200 | 1.97 |
| 10:01 ET | 650 | 1.94 |
| 10:03 ET | 3900 | 1.96 |
| 10:08 ET | 100 | 1.95 |
| 10:10 ET | 100 | 1.97 |
| 10:14 ET | 237 | 1.9509 |
| 10:15 ET | 1800 | 1.95 |
| 10:17 ET | 800 | 1.95 |
| 10:19 ET | 200 | 1.94 |
| 10:21 ET | 2013 | 1.96 |
| 10:24 ET | 500 | 1.96 |
| 10:26 ET | 3105 | 1.97 |
| 10:30 ET | 400 | 1.97 |
| 10:32 ET | 100 | 2 |
| 10:35 ET | 100 | 1.9755 |
| 10:39 ET | 450 | 1.9508 |
| 10:42 ET | 100 | 2 |
| 10:51 ET | 200 | 1.97 |
| 10:53 ET | 3080 | 1.98 |
| 10:55 ET | 10138 | 2.01 |
| 10:57 ET | 400 | 2.03 |
| 11:00 ET | 5600 | 2.045 |
| 11:02 ET | 1000 | 2.04 |
| 11:06 ET | 1800 | 2.03 |
| 11:08 ET | 3763 | 2.05 |
| 11:09 ET | 2622 | 2.045 |
| 11:13 ET | 700 | 2.04 |
| 11:15 ET | 100 | 2.07 |
| 11:18 ET | 351 | 2.0688 |
| 11:20 ET | 351 | 2.02 |
| 11:22 ET | 2821 | 2.07 |
| 11:24 ET | 600 | 2.07 |
| 11:31 ET | 500 | 2.03 |
| 11:44 ET | 116 | 1.99 |
| 11:47 ET | 280 | 2.0085 |
| 11:51 ET | 100 | 2.01 |
| 12:12 ET | 3095 | 1.988 |
| 12:14 ET | 100 | 2 |
| 12:16 ET | 1700 | 1.985 |
| 12:18 ET | 100 | 1.985 |
| 12:20 ET | 600 | 1.985 |
| 12:21 ET | 400 | 1.98 |
| 12:23 ET | 100 | 1.98 |
| 12:38 ET | 600 | 1.98 |
| 12:45 ET | 309 | 1.9802 |
| 12:50 ET | 1500 | 1.98 |
| 12:52 ET | 1971 | 1.98 |
| 12:54 ET | 300 | 1.98 |
| 12:56 ET | 100 | 1.98 |
| 01:01 ET | 1200 | 2 |
| 01:06 ET | 991 | 1.99 |
| 01:14 ET | 100 | 2 |
| 01:48 ET | 500 | 1.99 |
| 02:02 ET | 200 | 1.995 |
| 02:08 ET | 3700 | 1.98 |
| 02:09 ET | 693 | 1.98 |
| 02:18 ET | 100 | 1.985 |
| 02:24 ET | 400 | 1.98 |
| 02:26 ET | 900 | 1.97 |
| 02:27 ET | 500 | 1.975 |
| 02:29 ET | 100 | 1.9669 |
| 02:42 ET | 10902 | 1.95 |
| 02:44 ET | 100 | 1.95 |
| 02:47 ET | 1205 | 1.95 |
| 02:51 ET | 400 | 1.95 |
| 02:56 ET | 300 | 1.9519 |
| 03:00 ET | 200 | 1.955 |
| 03:09 ET | 200 | 1.9654 |
| 03:12 ET | 100 | 1.98 |
| 03:34 ET | 400 | 1.97 |
| 03:39 ET | 100 | 1.98 |
| 03:56 ET | 400 | 1.95 |
| 03:57 ET | 727 | 1.98 |
| 03:59 ET | 3420 | 1.99 |
Yesterday
Apr 18, 2024
DJ ProQR Therapeutics Is Maintained at Neutral by Citigroup, from 12:16PM ET on Thursday Apr 18, 2024 by Dow Jones
12:16PM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ProQR Therapeutics NV | 151.3M | -5.4x | --- |
Molecular Partners AG | 133.8M | -1.6x | --- |
Vaxart Inc | 146.4M | -1.3x | --- |
Syros Pharmaceuticals Inc | 124.9M | -0.8x | --- |
Mediwound Ltd | 161.3M | -20.5x | --- |
Generation Bio Co | 184.8M | -1.4x | --- |
Company Information
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Contact Information
- Headquarters
- Zernikedreef 9LEIDEN, Netherlands 2333 CK
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Supervisory Board
- Dinko Valerio
- Chairman of the Management Board, Chief Executive Officer
- Daniel de Boer
- Chief Financial Officer
- Jurriaan Dekkers
- Chief People and Operations Officer
- Sheila Sponselee
- Chief Scientific Officer
- Gerard Platenburg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.3M |
|---|---|
Revenue (TTM) | $10.1M |
Shares Outstanding | 81.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.31 |
EPS | $-0.37 |
Book Value | $0.52 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 14.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -314.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
